Categories
Uncategorized

New Report Exposes Human Cost of Involuntary Psychiatric Lockups

Behind the guise of “care,” psychiatry’s coercive system locks away 1.2 million people annually—fueling overdoses, suicides and billions in profit.

By Logan H. Merrill 

“History teaches us to beware of benefactors who deprive their beneficiaries of liberty.… There is neither justification nor need for involuntary psychiatric interventions.” —Professor Thomas Szasz

They needed an excuse.

The problem they chose to use was rising homelessness in America. In the Sixties, the “solution” they came up with was to simply round them up, whether they like it or not, for “treatment” (read “powerful brain-numbing drugs”).

But why stop with the homeless? Surely, there are many others out there who should be off the streets “for their own good” and lovingly nurtured by those who know better what’s best for them.

And so, Judgment Day comes early for many of society’s innocents.

Each year, more people are locked away in psychiatric wards against their will than in state and federal prisons.

They’re not being judged as sinners or saints, nor by an impartial jury from above.

Instead, they’re judged on the basis of “sanity”—with the judges being those who profit most from a thumbs-down verdict: psychiatrists.

This “trial”—for that’s what it truly is—offers no jury, no defense attorney, no due process. It takes only minutes and hides behind the euphemism “involuntary psychiatric evaluation.” The word “involuntary” is particularly cynical in its use, implying something that couldn’t be controlled but was bound to happen—like a burp or a sneeze.

Take a community like New York City. Last year, nearly 7,800 of its citizens were taken against their will for psychiatric evaluation. Most were not homeless, although that was the “problem” supposedly being addressed.

A July 2025 Federal Reserve Bank of New York report analyzed 16,630 involuntary psychiatric evaluations in Allegheny County, Pennsylvania, between 2014 and 2023. It found that 78 percent of these evaluations resulted in the next euphemism: “involuntary hospitalization” (read “coerced incarceration in violation of the victim’s human rights and the 14th Amendment requirement of due process”).

Involuntary hospitalizations have grown 3X faster than the US population

Each year, more people are locked away in psychiatric wards against their will than in state and federal prisons.

Since 2011, involuntary hospitalization rates have grown three times faster than the US population.

And today, an estimated 1.2 million people are detained against their will—often drugged and restrained—every 12 months. That’s more than double the mortality rate from cancer.

With numbers like these, you’d expect results—at least if “care” were the goal. So let’s crack open the ledger and see what passes for “results” in the psychiatric industry.

The July 2025 Federal Reserve Bank report found that those involuntarily hospitalized for psychiatric reasons were nearly twice as likely to die by suicide or overdose within three months of release. Earlier research paints an even darker picture: A 2014 study of 50,000 cases found psychiatric hospitalization raised suicide risk by 44 times, while a 2017 study put the figure at 100 times greater than average immediately after psychiatric discharge.

Harvard Public Health tracked 22 individuals after their involuntary hospitalization. All relapsed within a year. Two died.

Pim Welle, co-author of the July report, has stated that the findings establish conclusively a link between involuntary hospitalization and harm—be it suicide, overdose or violence—after discharge.

And as for that “homelessness problem”—the original pretext for mass psychiatric roundups—Jan Eastgate, president of mental health watchdog Citizens Commission on Human Rights, states: “Involuntary psychiatric commitment of the homeless is not a compassionate solution—it’s a costly, coercive and dangerous policy built on a system that has failed for decades. It compounds trauma, violates civil rights and channels billions into an industry that cannot cure, only control.”

In fact, homelessness went up with the growth of so-called “street psychiatry”—by 80,000 from 2015 to 2023.

“Forced treatment in psychiatry is a crime against humanity.”

These statistics are appalling. We find them appalling. You find them appalling. Anyone with a teaspoon of common sense finds them appalling.

Why don’t psychiatrists see what we see?

Because their noses are in a different ledger—one labeled “Profits.”

Involuntary psychiatric hospitalization puts up to $1.1 million per person annually into psychiatric coffers.

Continue reading here.

Categories
Uncategorized

Regulators Sound Alarm on ADHD Drug Atomoxetine “Side Effects” Suicide and Homicide

Drug regulatory agencies in Germany and Australia have added warnings that atomoxetine can trigger violent or suicidal thoughts—sparking urgent concern over its long‑term use in children and adults.

Why on God’s little green earth would you give your child a drug that experts say can make them homicidal or suicidal?

And why would you ever take such a drug yourself?

The answer is: You wouldn’t. But for well over 20 years, millions of Americans have been taking—and giving their kids—the psychiatric drug atomoxetine.

And now, drug regulatory agencies in both Germany and Australia have issued warnings that the drug can cause homicidal and suicidal behavior and thoughts.

That’s right—the drugs you’re giving your children on the advice of psychiatrists can make them want to kill you.

“The idea that a drug prescribed to millions of children and adults could induce homicidal behavior is nothing short of astonishing.”

Read more here.

Categories
Uncategorized

Psychiatrist Exposes the “Chemical Imbalance” Lie of Her Own Profession in New Book

Psychiatrist Joanna Moncrieff indicts her entire industry for falsely pushing deadly drugs as a “treatment” for depression. Her conclusion: They don’t work. And she’s got the evidence to prove it. 

This was not on their Bingo card.

The psychiatric community awoke one morning in mid-January to find the foundations of their cash-cow alliance with Big Pharma yanked out from underneath them—and by one of their own.

A new history of antidepressants, authored by a psychiatrist, doesn’t so much make the case for the falsehood of the chemical treatment of depression as it does annihilate it.

Granularly researched with evidence as airtight as it is brutal, Chemically Imbalanced: The Making and Unmaking of the Serotonin Myth by Dr. Joanna Moncrieff, a professor of psychiatry at University College London, indicts and convicts her entire industry for knowingly hawking deadly drugs on the for-profit pretense of “treating” depression.

Dr. Moncrieff resolved to unmask the fraud after leading a team of five top UK and European specialists on a review of studies to determine if there was, in fact, a relationship between the chemical serotonin and depression. Since the 1960s, psychiatrists have insisted—in articles, papers, websites and every platform they could shout from—that a “below-normal” amount of the so-called “feel-good” chemical serotonin is the cause of misery. Then, with the advent of “Selective Serotonin Reuptake Inhibitor” (SSRI) antidepressants in the 1990s, “chemical imbalance” became the Golden Calf psychiatrists and pharmaceutical giants worshipped: Simply jack up the depressed person’s serotonin with antidepressant snake-oil drugs that enrich psychiatrists and Big Pharma and thus remedy that “chemical imbalance.”

But Dr. Moncrieff and her team have thrown cold water on the “you’re-depressed-because-you-need-your-chemicals-rebalanced” party. In findings published in the journal Molecular Psychiatry, she concluded that “there is no evidence of a connection between reduced serotonin levels of activity and depression.”

Read the rest of this article here.

Categories
Uncategorized

New Research Finds Dangerous Psychedelic Drugs Misrepresented by Psychiatry

With profit as the most obvious motive, psychiatry is pushing dangerous psychedelic drugs at every turn. New research studies are pushing back.

A profiteering pack of psychiatrists have a new money horse to ride into town: trippy hallucinogenic drugs to “cure” every ailment from depression to addiction to anxiety to schizophrenia.

Excited reports from “studies” praise the effects of the brain-scrambling drugs. Just hop on the hokum train, grab a bottle of whatever psychedelic mixture they’re peddling this week, take a big old swig and—they swear—overnight you’ll be right as rain. And, they claim, a growing body of clinical trials say it’s so. Scads of them are currently underway on various psychedelic drugs, from the date-rape drug ketamine to psilocybin and even LSD.

But a daring and concerned group of researchers at the University of Rennes in France has gone against the money-grubbing psychiatric trend, leading a new study of existing clinical trial reports. The researchers found that psychedelics have been wildly misrepresented, inaccurate claims of study results have been improperly exaggerated and the dangers of the drugs have been seriously minimized.

Read the full article here.

Categories
Uncategorized

CCHR Commends FDA Decision: Psychedelic Drug Ecstasy Not Proven Safe or Effective Treatment for Traumatized Patients

By CCHR National

The U.S. drug regulatory agency examined evidence presented by the company requesting approval for MDMA (ecstasy) and reports from experts examining that evidence before denying approval for the drug as mental health treatment. A medical journal has just retracted three MDMA therapy research papers for ethical violations.

Washington, DC – August 13, 2024 — The U.S. Food and Drug Administration (FDA) has rejected the psychedelic drug MDMA, commonly known as ecstasy or molly, as treatment for post-traumatic stress, a decision that Citizens Commission on Human Rights (CCHR) advocated in its statement submitted to the FDA during a public comment period earlier this year. The FDA’s decision ends the first attempt to gain the agency’s approval for a psychedelic drug treatment.

The FDA concurred with the findings of its advisory committee of independent experts, which held a public hearing in June on the use of MDMA for psychedelic-assisted psychotherapy. The committee voted overwhelmingly that the company which applied for drug approval, Lykos Therapeutics, failed in its clinical trials to prove the treatment was effective, and that benefits from the drug therapy did not outweigh the risks.  READ MORE

error

Don't miss out on new articles:

RSS